{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:30:55Z","timestamp":1790188255367,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["107752\/z\/15\/z"],"award-info":[{"award-number":["107752\/z\/15\/z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The two non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz (EFV) and nevirapine (NVP), are currently the core antiretroviral drugs for treatment of HIV in sub-Saharan Africa including Botswana. The drugs are metabolized by Cytochrome P450 2B6 (<jats:italic toggle=\"yes\">CYP2B6<\/jats:italic>) liver enzyme. The <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic> gene that encodes for metabolism of these drugs is known to be highly polymorphic. One of the polymorphism in the <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic> gene, 516G&gt;T, particularly the 516T allele, is known to confer poor metabolism of EFV and NVP. This may lead to high levels of plasma drug concentrations and development of treatment toxicities, like central nervous system toxicities, and cutaneous and hepatic toxicities, for EFV and NVP, respectively. The <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic> 516G allele on the other hand is associated with an extensive metabolism of the two NNRTIs drugs. We sought to establish association between possible developments of NNRTIs toxicities with <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic> 516G&gt;T variation in Botswana.<\/jats:p>\n            <jats:p>A total of 316 peripheral blood mononuclear cells samples were used in a retrospective view. All the samples were from participants on EFV\/NVP-containing regimen with known toxicity output. TaqMan Real-Time PCR approach was applied for assessing <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic> 516 allele variation in cases with treatment toxicity and those without. Analysis was performed by chi-square statistics and logistic regression analysis.<\/jats:p>\n            <jats:p>The rate of poor metabolizers among participants with toxicity and those without toxicity was 18.4% and 15.1%, respectively. The <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic> 516 genotype distribution comparisons between the participants with toxicity and those without were not statistically different (chi-square\u200a=\u200a.326; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.568).<\/jats:p>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic> 516 variation was not associated with NNRTI toxicity. No other factors were associated with toxicity when considering age, baseline body mass index, baseline CD4, baseline HIV viral load and adherence. The results were discussed in the context of all the studies done in Botswana to date.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029066","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T19:01:46Z","timestamp":1651777306000},"page":"e29066","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The role of CYP2B6 516G&gt;T polymorphism on efavirenz\/nevirapine toxicity. Implications on treatment outcomes"],"prefix":"10.1097","volume":"101","author":[{"given":"Monkgomotsi J.","family":"Maseng","sequence":"first","affiliation":[{"name":"School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, UB Campus, Block 246, Gaborone, Botswana"},{"name":"Botswana-Harvard AIDS Institute Partnership, Plot 1836 North Ring Road, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leabaneng","family":"Tawe","sequence":"additional","affiliation":[{"name":"School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, UB Campus, Block 246, Gaborone, Botswana"},{"name":"Botswana-Harvard AIDS Institute Partnership, Plot 1836 North Ring Road, Gaborone, Botswana"},{"name":"Botswana-University of Pennsylvania Partnership, UB Campus, Block 244G, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisca K.","family":"Thami","sequence":"additional","affiliation":[{"name":"Botswana-Harvard AIDS Institute Partnership, Plot 1836 North Ring Road, Gaborone, Botswana"},{"name":"Division of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Anzio Road Observatory, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikhulile","family":"Moyo","sequence":"additional","affiliation":[{"name":"Botswana-Harvard AIDS Institute Partnership, Plot 1836 North Ring Road, Gaborone, Botswana"},{"name":"Department of Immunology and Infectious Diseases, Harvard School of Public Health, 677 Hungtinton Avenue, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishmael","family":"Kasvosve","sequence":"additional","affiliation":[{"name":"School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, UB Campus, Block 246, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Novitsky","sequence":"additional","affiliation":[{"name":"Botswana-Harvard AIDS Institute Partnership, Plot 1836 North Ring Road, Gaborone, Botswana"},{"name":"Department of Immunology and Infectious Diseases, Harvard School of Public Health, 677 Hungtinton Avenue, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Essex","sequence":"additional","affiliation":[{"name":"Botswana-Harvard AIDS Institute Partnership, Plot 1836 North Ring Road, Gaborone, Botswana"},{"name":"Department of Immunology and Infectious Diseases, Harvard School of Public Health, 677 Hungtinton Avenue, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Disease, Faculty of Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simani","family":"Gaseitsiwe","sequence":"additional","affiliation":[{"name":"Botswana-Harvard AIDS Institute Partnership, Plot 1836 North Ring Road, Gaborone, Botswana"},{"name":"Department of Immunology and Infectious Diseases, Harvard School of Public Health, 677 Hungtinton Avenue, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0751-0682","authenticated-orcid":false,"given":"Giacomo M.","family":"Paganotti","sequence":"additional","affiliation":[{"name":"Botswana-University of Pennsylvania Partnership, UB Campus, Block 244G, Gaborone, Botswana"},{"name":"Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, 3120-2740 Hamilton Walk, Philadelphia, PA"},{"name":"Department of Biomedical Sciences, Faculty of Medicine, University of Botswana, UB Campus, Block 246, Gaborone, Botswana."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1186\/s12879-021-06757-6","article-title":"Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study [published correction appears in BMC Infect Dis. 2021 Oct 25;21(1):1098]","volume":"21","author":"Riou","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/hiv.12488","article-title":"Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms: a substudy of the ANRS ALIZE trial","volume":"18","author":"Gallien","year":"2017","journal-title":"HIV Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.meegid.2015.11.014","article-title":"Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments","volume":"37","author":"Russo","year":"2016","journal-title":"Infect Genet Evol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1038\/s41598-018-23350-1","article-title":"Human cytochrome P450 2B6 genetic variability in Botswana: a case of haplotype diversity and convergent phenotypes","volume":"8","author":"Tawe","year":"2018","journal-title":"Sci Rep"},{"key":"R8-20250504","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41397-018-0028-2","article-title":"Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana","volume":"18","author":"Vujkovic","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s13365-012-0120-3","article-title":"Antiretroviral neurotoxicity","volume":"18","author":"Robertson","year":"2012","journal-title":"J Neurovirol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R12-20250504","first-page":"335","article-title":"Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [published correction appears in Pharmgenomics Pers Med. 2021 Mar 31;14:395]","volume":"14","author":"Maseng","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/QAI.0000000000001442","article-title":"Brief report: CYP2B6 516G>T minor allele protective of late virologic failure in efavirenz-treated HIV-infected patients in Botswana","volume":"75","author":"Vujkovic","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2334-13-261","article-title":"Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study","volume":"13","author":"Mukonzo","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1097\/QAD.0000000000001593","article-title":"CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana","volume":"31","author":"Gross","year":"2017","journal-title":"AIDS"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11011-008-9109-2","article-title":"Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity","volume":"23","author":"Streck","year":"2008","journal-title":"Metab Brain Dis"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/QAI.0b013e31817c1ed0","article-title":"Slow efavirenz metabolism genotype is common in Botswana","volume":"49","author":"Gross","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/pds.3615","article-title":"Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences","volume":"23","author":"Sonenthal","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13318-018-0507-5","article-title":"Impact of efavirenz metabolism on loss to care in older HIV+ Africans","volume":"44","author":"Torgersen","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"(Suppl 1)","key":"R21-20250504","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/01.aids.0000366080.91192.55","article-title":"Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana","volume":"24","author":"Wester","year":"2010","journal-title":"AIDS"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","article-title":"Disposition and biotransformation of the antiretroviral drug nevirapine in humans","volume":"27","author":"Riska","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/dmd.31.1.122","article-title":"Metabolism of (S)-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics","volume":"31","author":"Chen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2009.03368.x","article-title":"CYP2B6 (c.516G-->T) and CYP2A6 (\u22179B and\/or \u221717) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients","volume":"67","author":"Kwara","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1128\/AAC.02069-13","article-title":"Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi","volume":"58","author":"Dickinson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20250504","first-page":"13","article-title":"Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the Mozambican population","volume":"20","author":"Arnaldo","year":"2013","journal-title":"Malays J Med Sci"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","article-title":"Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa","volume":"14","author":"Cohen","year":"2009","journal-title":"Antivir Ther"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1875692111201010043","article-title":"CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 polymorphisms in two bantu-speaking populations from Cameroon and South Africa: implications of global pharmacogenetics","volume":"10","author":"Swart","year":"2012","journal-title":"Curr Pharmacogenomics Person Med"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/FPC.0b013e328363176f","article-title":"High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV\/AIDS patients","volume":"23","author":"Swart","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bcp.12590","article-title":"Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa","volume":"80","author":"Sinxadi","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1089\/omi.2017.0078","article-title":"CYP2B6 haplotype predicts efavirenz plasma concentration in Black South African HIV-1-infected children: a longitudinal pediatric pharmacogenomic study","volume":"21","author":"Reay","year":"2017","journal-title":"OMICS"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","article-title":"High prevalence of the CYP2B6 516G->T (\u22176) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe","volume":"64","author":"Nyakutira","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1093\/jac\/dkq369","article-title":"Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection","volume":"65","author":"Jamshidi","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-011-1118-0","article-title":"CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans","volume":"68","author":"Maimbo","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"04","DOI":"10.1186\/s40360-015-0004-2","article-title":"CYP2B6\u22176, CYP2B6\u221718, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV\/AIDS and TB cohort in Zimbabwe","volume":"16","author":"Dhoro","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ebiom.2015.05.012","article-title":"Investigation of efavirenz discontinuation in multiethnic populations of HIV-positive individuals by genetic analysis","volume":"2","author":"Cummins","year":"2015","journal-title":"EBioMedicine"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/humu.22295","article-title":"Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools","volume":"34","author":"Radloff","year":"2013","journal-title":"Hum Mutat"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3389\/fgene.2019.00905","article-title":"Population structure and implications on the genetic architecture of HIV-1 phenotypes within southern Africa","volume":"10","author":"Thami","year":"2019","journal-title":"Front Genet"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.12688\/aasopenres.12965.1","article-title":"African Pharmacogenomics Consortium: consolidating pharmacogenomics knowledge, capacity development and translation in Africa","volume":"2","author":"Dandara","year":"2019","journal-title":"AAS Open Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:14:06Z","timestamp":1746328446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029066"}},"subtitle":["Lessons from Botswana"],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":39,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029066","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"2022-01-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}